Dabrafenib, Trametinib Decrease Death Risk in Metastatic Melanoma
the Cancer Therapy Advisor take:
GlaxoSmithKline has announced overall survival results from the phase III COMBI-d study which show a statistically significant reduction in the risk of death (HR = 0.71; 95% CI: 0.55 - 0.92; P = 0.011) for the combination of dabrafenib and trametinib compared with dabrafenib alone in patients with BRAF V600E/K mutation-positive metastatic melanoma.
COMBI-d is a double-blind, international study that compared the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, to dabrafenib plus placebo in patients with stage IIIC or IV BRAF V600E/K mutation-positive cutaneous melanoma. The study included 423 patients that were randomly assigned to either arm.
Previous analyses showed that the combination decreased the risk of disease progression and/or death by 25% compared with dabrafenib alone (HR = 0.75; 95% CI: 0.57 - 0.99; P = 0.035).
Results showed a median progression-free survival of 9.3 months and 8.8 months in the combination and dabrafenib alone groups, respectively.
Trametinib and dabrafenib have already been approved by the U.S. Food and Drug Administration to be used in combination for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma.
Trametinib and dabrafenib have already been approved by the FDA for unresectable or metastatic melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia